Eftekharian Hamid Reza, Ilkhani Pak Homa
Department of Oral and Maxillofacial Surgery, Shiraz University of Medical Sciences, Shiraz, Iran.
Student Research Committee, School of Dentistry, Shiraz University of Medical Science, Shiraz, Iran.
Bull Emerg Trauma. 2017 Jan;5(1):13-17.
To evaluate the effects of intravenous ketorolac on early postoperative pain in patients with mandibular fractures, who underwent surgical repair.
This prospective, randomized, placebo-controlled clinical trial was conducted in Shahid Rajaei Hospital, affiliated with Shiraz University of Medical Sciences during a 1-year period from 2015 to 2016. We included a total number of 50 patients with traumatic mandibular fractures who underwent surgical repair. Patients with obvious contraindications to ketorolac such as asthma, renal dysfunction, peptic ulceration, bleeding disorders, cardiovascular disease, mental retardation, or allergy to ketorolac or NSAIDS, were excluded. The patients were randomly assigned to receive intravenous ketorolac (30 mg) at the end of operation in post anesthesia care unit immediately upon the onset of pain (n=25), or intravenous distilled water as placebo (n=25). Postoperative monitoring included non-invasive arterial blood pressure, ECG, and peripheral oxygen saturation. The postoperative pain was evaluated by a nurse using visual analog scale (VAS) (0-100 mm) pain score 4 hours after surgery and was compared between the two study groups.
Overall we included 50 patients (25 per group) in the current study. The baseline characteristics including age, gender, weight, operation duration, anesthesia duration and type of surgical procedure were comparable between two study groups. Those who received placebo had significantly higher requirements for analgesic use compared to ketorolac group (72% 28%; ). Ketorolac significantly reduced the pain intensity 30-min after the operation (p<0.001). There were no significant side effects associated with ketorolac.
Intravenous single-dose ketorolac is a safe and effective analgesic agent for the short-term management of mild to moderate acute postoperative pain in mandibular fracture surgery and can be used as an alternative to opioids.
评估静脉注射酮咯酸对接受手术修复的下颌骨骨折患者术后早期疼痛的影响。
这项前瞻性、随机、安慰剂对照临床试验于2015年至2016年在设拉子医科大学附属的沙希德拉贾伊医院进行,为期1年。我们纳入了总共50例接受手术修复的创伤性下颌骨骨折患者。排除有明显酮咯酸禁忌证的患者,如哮喘、肾功能不全、消化性溃疡、出血性疾病、心血管疾病、智力低下或对酮咯酸或非甾体抗炎药过敏者。患者被随机分配在麻醉后护理单元手术结束疼痛发作时立即静脉注射酮咯酸(30毫克)(n = 25),或静脉注射蒸馏水作为安慰剂(n = 25)。术后监测包括无创动脉血压、心电图和外周血氧饱和度。术后疼痛由护士在术后4小时使用视觉模拟量表(VAS)(0 - 100毫米)疼痛评分进行评估,并在两个研究组之间进行比较。
本研究共纳入50例患者(每组25例)。两个研究组之间的基线特征,包括年龄、性别、体重、手术持续时间、麻醉持续时间和手术方式具有可比性。与酮咯酸组相比,接受安慰剂的患者对镇痛药物的需求显著更高(72% 对28%)。酮咯酸在术后30分钟显著降低了疼痛强度(p < 0.001)。酮咯酸没有显著的副作用。
静脉注射单剂量酮咯酸是下颌骨骨折手术中短期管理轻至中度急性术后疼痛的一种安全有效的镇痛剂,可作为阿片类药物的替代品。